|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Among 32-36 week births, all minority groups had higher risk of death from congenital anomalies than White British, the highest rate ratios being 4.50 (3.78 to 5.37) for Pakistani, 2.89 (2.10 to 3.97) for Bangladeshi and 2.06 (1.59 to 2.68) for Black African; risks of death from congenital anomalies and combined rarer causes (infection, intrapartum conditions, SIDS and unclassified) increased with deprivation, the rate ratios comparing the most with the least deprived quintile being, respectively, 1.54 (1.22 to 1.93) and 2.05 (1.55 to 2.72).
|
31123058 |
2020 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
|
31022913 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Iduronate-2-Sulfatase-Regulated Dermatan Sulfate Levels Potentiate the Invasion of Breast Cancer Epithelia through Collagen Matrix.
|
31574977 |
2019 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In the context of our demonstration that DS enhances the elastic modulus of Type 1 collagen gels, we propose that a decrease of IDS expression leads to accumulation within cancer epithelia of DS: the latter remodels the collagen around cancer cells leading to changes in cell shape and invasiveness through fibrillar matrix milieu.
|
31574977 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We observed that mRNA expression of the sulfatases GALNS, GNS and IDS was increased, while protein expression of many sulfatases was decreased in COPD fibroblasts.
|
30760748 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Iduronate-2-Sulfatase-Regulated Dermatan Sulfate Levels Potentiate the Invasion of Breast Cancer Epithelia through Collagen Matrix.
|
31574977 |
2019 |
|
Chronic myeloproliferative disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Members of the IDS were invited to submit any case of histologically confirmed MPD, as well as other benign and malignant dermatoses that involve the nipple and areola complex.
|
31270878 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In the context of our demonstration that DS enhances the elastic modulus of Type 1 collagen gels, we propose that a decrease of IDS expression leads to accumulation within cancer epithelia of DS: the latter remodels the collagen around cancer cells leading to changes in cell shape and invasiveness through fibrillar matrix milieu.
|
31574977 |
2019 |
|
Glycogen storage disease type II
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on different enzyme properties in uncultured CV, different prenatal diagnostic strategies should be adopted for MPS II and Pompe disease.
|
29966168 |
2018 |
|
Hypercalcemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This case of NSHPT suggests that a near-miss event, labelled as a possible case of SIDS, could also be due to severe hypercalcemia and evidentiates the difficulties of the neonatal management of NSHPT.
|
30376845 |
2018 |
|
Leukodystrophy, Metachromatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
When FGE is absent or insufficient, all 17 known human sulfatases are affected, including the enzymes associated with metachromatic leukodystrophy (MLD), several mucopolysaccharidoses (MPS II, IIIA, IIID, IVA, VI), chondrodysplasia punctata, and X-linked ichthyosis.
|
29397290 |
2018 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Since IDS catalyzes the degradation of glycosaminoglycans (GAGs), deficiency in this enzyme leads to accumulation of GAGs in most cells in all tissues and organs, resulting in severe somatic and neurological disorders.
|
29606503 |
2018 |
|
Sleep disturbances
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Sleep disturbances and behavioral problems occur early in MPS II and III with features of externalizing disorders.
|
30442188 |
2018 |
|
Post-Traumatic Stress Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Women whose PTSD scores were in the highest quartile were most likely to access services; 45% of surveyed women used SIDS and Kids of the Australian Capital Territory (SKACT) accessing counselling (90%), support groups (50%), playgroups (15%) and the helpline (10%).
|
28656585 |
2018 |
|
Ichthyosis, X-Linked
|
0.010 |
Biomarker
|
disease |
BEFREE |
When FGE is absent or insufficient, all 17 known human sulfatases are affected, including the enzymes associated with metachromatic leukodystrophy (MLD), several mucopolysaccharidoses (MPS II, IIIA, IIID, IVA, VI), chondrodysplasia punctata, and X-linked ichthyosis.
|
29397290 |
2018 |
|
Antiphospholipid Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Therefore we decided to test the performance of a new chemiluminescent assay (CLIA), and assayed aCL and aβ2-GPI IgG/M in serum from 120 healthy individuals, 108 patients with idiopathic venous thrombosis, 78 patients with antiphospholipid syndrome (APS), and 64 non-thrombotic APLA-carriers using CLIA IDS-iSYS.
|
30017909 |
2018 |
|
Photopsia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The macular pigment optical density (MPOD) of a Japanese population was measured using a commercially based heterochromatic flicker photometer, the Macular Pigment Screener (MPS2).
|
29594609 |
2018 |
|
Rumination Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
DSM-IV diagnoses were assessed with the CIDI, symptom severity with the IDS and BAI, and RNT with measures for perseverative thinking (PTQ), rumination (LEIDS-R) and worry (PWQ).
|
30138805 |
2018 |
|
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Sleep disturbances and behavioral problems occur early in MPS II and III with features of externalizing disorders.
|
30442188 |
2018 |
|
Memory impairment
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MPS II mice presented impaired memory at 6 months evaluated by open field test.
|
28918469 |
2018 |
|
Impaired cognition
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The rare disease, Hunter Syndrome (mucopolysaccharidosis type II; MPS II), characterized by iduronate-2-sulfatase deficiency, has heterogeneous symptoms often including cognitive impairment (CI).
|
30409228 |
2018 |
|
Generalized glycogen storage disease of infants
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on different enzyme properties in uncultured CV, different prenatal diagnostic strategies should be adopted for MPS II and Pompe disease.
|
29966168 |
2018 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conclusions We confirm previous findings concerning the non-superiority of NACT + IDS compared to PDS for the treatment of EOC, even if NACT + IDS treatment was associated with significant lower rate of post-operative complications.
|
30210049 |
2018 |
|
perseverative thinking
|
0.010 |
Biomarker
|
disease |
BEFREE |
DSM-IV diagnoses were assessed with the CIDI, symptom severity with the IDS and BAI, and RNT with measures for perseverative thinking (PTQ), rumination (LEIDS-R) and worry (PWQ).
|
30138805 |
2018 |
|
Sleep Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Sleep disturbances and behavioral problems occur early in MPS II and III with features of externalizing disorders.
|
30442188 |
2018 |